Active — Not RecruitingNot Applicable

Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.

Japan1 participantsStarted 2024-07-30

Plain-language summary

To investigate the safety and efficacy in patients with relapsed and refractory multiple myeloma treated with elranatamab under the actual use.

Age range16 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Patients who have received at least one dose of elranatamab.

Incidence of CRS events in adverse drug reaction

Timeframe: up to 52 weeks

Incidence of ICANS events in adverse drug reaction

Timeframe: up to 52 weeks

NCT IDNCT06479954

SponsorPfizer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2027-02-25